Cancer precision diagnostics startup Pairidex raised $4.89 million in a seed round to advance FusionMRD, an RNA-based droplet digital PCR blood test for monitoring minimal residual disease in fusion-driven blood cancers. The company said it will use proceeds for commercialization acceleration, additional clinical studies, and platform development. Pairidex indicated that FusionMRD is already commercially available through its CLIA-certified, CAP-accredited lab and that it focuses initially on AML patients with gene fusions—an estimated segment of the AML population. The oversubscribed seed highlights continued investor support for MRD as a decision-support layer in oncology, particularly where RNA fusion biomarkers can improve sensitivity and reduce reliance on tissue sampling.